{"meta":{"query_hash":"137bacb60294","filters":{"venue":"05.01 - Airway pharmacology and treatment"},"cohort_total":11,"direct_labels_cover":0,"predictions_cover":11,"exported":11,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/137bacb60294","api":"https://metacan.xera.ac/api/v1/cohort?venue=05.01+-+Airway+pharmacology+and+treatment"},"results":[{"id":"W4312280085","doi":"10.1183/13993003.congress-2022.2256","title":"Relation between reduction in fractional exhaled nitric oxide and efficacy in asthma patients treated with dupilumab","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Dupilumab; Exhaled nitric oxide; Medicine; Placebo; Exacerbation; Asthma; Internal medicine; Bronchodilator; Gastroenterology; Lung function; Lung; Pathology; Spirometry","score_opus":0.01349194521835311,"score_gpt":0.2804429612581072,"score_spread":0.2669510160397541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312280085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998299,0.00048658586,0.000001984243,0.00019546595,0.000045014098,0.0007642141,0.000021650025,0.000027495988,0.00015859617],"genre_scores_gemma":[0.99896294,0.00011739491,0.000026198815,0.00006901403,0.00006432936,0.00024324808,0.00022501916,0.000014627974,0.00027723605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989549,0.00018739869,0.00021795301,0.00031790847,0.00013830094,0.00018352037],"domain_scores_gemma":[0.99962956,0.00008435775,0.00008571233,0.00006368605,0.000022242064,0.00011443563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007239233,0.00016387217,0.00026143517,0.00030929162,0.00018149038,0.0000044985823,0.000019461982,0.000065063614,0.00024939934],"category_scores_gemma":[0.0000050893955,0.0001302145,0.000030250972,0.0002737201,0.00007299705,0.00008439193,0.000023577903,0.00020026127,0.0000040481145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028512415,0.002407887,0.9669102,0.000012171285,0.00013126286,0.00020001995,0.00011518092,0.00021486788,0.00045977908,0.0000043439695,0.00012547536,0.026567591],"study_design_scores_gemma":[0.01928003,0.0024826291,0.97498935,0.000015329633,0.00022396423,0.000050768107,0.00012050186,0.00010576175,0.00058534794,0.0000069306548,0.0020283961,0.000111006004],"about_ca_topic_score_codex":0.00010117597,"about_ca_topic_score_gemma":0.0000068541444,"teacher_disagreement_score":0.026456585,"about_ca_system_score_codex":0.0003711115,"about_ca_system_score_gemma":0.00008779455,"threshold_uncertainty_score":0.5309993},"labels":[],"label_agreement":null},{"id":"W4312294278","doi":"10.1183/13993003.congress-2022.1020","title":"Reduction in work and activity impairment within 6 months of benralizumab initiation in Canadians with severe eosinophilic asthma","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Pediatric health and respiratory diseases","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; University of Regina; University of Calgary; Vitalité Health Network; McMaster University; Barrie Urology Group; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; AstraZeneca (Canada); University of Alberta; University of Saskatchewan","funders":"","keywords":"Benralizumab; Medicine; Absenteeism; Asthma; Internal medicine; Physical therapy; Eosinophil; Mepolizumab; Psychology","score_opus":0.025383369555399625,"score_gpt":0.347704283367291,"score_spread":0.3223209138118914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312294278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953904,0.0008715168,8.823672e-7,0.0017493444,0.00026095033,0.0014165164,0.00011572946,0.000018313678,0.00017633184],"genre_scores_gemma":[0.9978686,0.00034246588,0.000019001745,0.0004490303,0.00007947154,0.0010895511,0.000027434498,0.0000122450865,0.00011217606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798006,0.00088163186,0.00033970992,0.00029561995,0.00011648161,0.00038649744],"domain_scores_gemma":[0.9993093,0.00014819352,0.00020166705,0.000089486224,0.000021469648,0.00022987874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029427497,0.00015992549,0.00029000948,0.00026006132,0.00047254414,0.000002026197,0.000040047882,0.00009395429,0.00024118081],"category_scores_gemma":[0.0000072038506,0.00013342484,0.000019980675,0.00033344366,0.000068995105,0.000091586066,0.00004222862,0.00033749925,0.0000012437908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006648395,0.0022348457,0.9550316,0.00032387764,0.00012063217,0.00030881522,0.011427095,0.0031094202,0.00018137138,0.00007475992,0.0015745668,0.018964626],"study_design_scores_gemma":[0.014320087,0.004218496,0.9730642,0.00006063192,0.00014197135,0.000029565872,0.004536613,0.00022223237,0.00019359082,0.00008253782,0.0028567945,0.0002733171],"about_ca_topic_score_codex":0.008969445,"about_ca_topic_score_gemma":0.008184992,"teacher_disagreement_score":0.018691309,"about_ca_system_score_codex":0.0009586088,"about_ca_system_score_gemma":0.0011333665,"threshold_uncertainty_score":0.99762994},"labels":[],"label_agreement":null},{"id":"W4312468892","doi":"10.1183/13993003.congress-2022.801","title":"Characteristics of Participants with Refractory Chronic Cough Enrolled in A Phase 2b Trial of BLU-5937","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Respiratory and Cough-Related Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bellus Health (Canada)","funders":"","keywords":"Demographics; Placebo; Medicine; Refractory (planetary science); Population; Randomized controlled trial; Internal medicine; Exploratory analysis; Demography","score_opus":0.046963237389640484,"score_gpt":0.37643598631833897,"score_spread":0.3294727489286985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312468892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624944,0.0012970513,0.0000026407179,0.00028575378,0.00023301721,0.0014077924,0.00006931881,0.000015361828,0.00043963862],"genre_scores_gemma":[0.99706644,0.0013455293,0.000009542608,0.00009664212,0.0001088426,0.000626549,0.000038309143,0.000018661896,0.0006894786],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99816406,0.00037331527,0.00050673995,0.00029993907,0.00027931744,0.00037663922],"domain_scores_gemma":[0.99917376,0.00019606405,0.00022682814,0.00019418423,0.00005349152,0.00015565915],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038604563,0.00019425538,0.00069949456,0.00018739744,0.00012052797,0.0000027749275,0.00007709172,0.00008962158,0.0016890813],"category_scores_gemma":[0.000016515422,0.00014260558,0.00008092195,0.0002505013,0.00024426886,0.00004469486,0.000055492234,0.0003583922,0.000004423677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7372401,0.03754688,0.015747307,0.000372833,0.00349321,0.004247255,0.0029885217,0.00022204636,0.12432882,0.00009746433,0.00081391505,0.07290167],"study_design_scores_gemma":[0.7025454,0.15470873,0.008963225,0.00010948986,0.0022064678,0.00009281323,0.00049605145,0.0010760725,0.100166455,0.000022347074,0.029256314,0.0003566557],"about_ca_topic_score_codex":0.000043175907,"about_ca_topic_score_gemma":0.000015281319,"teacher_disagreement_score":0.11716185,"about_ca_system_score_codex":0.00029649763,"about_ca_system_score_gemma":0.00069146557,"threshold_uncertainty_score":0.99922353},"labels":[],"label_agreement":null},{"id":"W4312533237","doi":"10.1183/13993003.congress-2022.3394","title":"Association between sub-optimal medication adherence and risk of COPD diagnosis in patients with physician-diagnosed asthma: A propensity score-based analysis","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Asthma; COPD; Hazard ratio; Propensity score matching; Internal medicine; Confidence interval; Cohort; Proportional hazards model; Incidence (geometry); Population; Cohort study; Marginal structural model; Relative risk","score_opus":0.024819562596541334,"score_gpt":0.2810162613251445,"score_spread":0.2561966987286032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312533237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978719,0.00022935949,0.00008966852,0.0006180486,0.000048578717,0.0009663891,0.000109934175,0.000018268574,0.00004786406],"genre_scores_gemma":[0.99786633,0.000498266,0.00012908078,0.00023703843,0.000026603242,0.0008706273,0.00028817437,0.000007851165,0.00007601184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985718,0.00028619773,0.00027846496,0.0003523138,0.00032172582,0.00018945806],"domain_scores_gemma":[0.9989372,0.00029430134,0.00042049654,0.00013647652,0.00009393046,0.000117593285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027052662,0.00015805413,0.00048394297,0.00017754578,0.00015648002,0.0000048228476,0.00005643242,0.000056488392,0.0003881724],"category_scores_gemma":[0.000028734752,0.00012663596,0.000054542004,0.00051922025,0.000103144564,0.00005678834,0.000031756525,0.00018162494,0.0000064860833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005767622,0.0014335767,0.98155534,0.00002303982,0.0014608064,0.000010706917,0.00016133612,0.0001589927,0.000040670333,0.000002376829,0.00050311314,0.014073266],"study_design_scores_gemma":[0.009268371,0.00280765,0.98094285,0.000025584659,0.003260004,3.169232e-7,0.000050274615,0.0006209636,0.0026491284,0.0000054379293,0.00026549288,0.000103907914],"about_ca_topic_score_codex":0.00031685532,"about_ca_topic_score_gemma":0.000092127484,"teacher_disagreement_score":0.013969358,"about_ca_system_score_codex":0.00029153796,"about_ca_system_score_gemma":0.00015062318,"threshold_uncertainty_score":0.5164065},"labels":[],"label_agreement":null},{"id":"W4312603183","doi":"10.1183/13993003.congress-2022.1025","title":"Sustained improvement of asthma control over 6 months of benralizumab treatment in Canadians with severe asthma","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; University of Alberta; Vitalité Health Network; McMaster University; Barrie Urology Group; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Impact; University of Regina; University of Calgary; AstraZeneca (Canada)","funders":"","keywords":"Benralizumab; Medicine; Minimal clinically important difference; Asthma; Interim analysis; Internal medicine; Cohort; Randomization; Randomized controlled trial; Eosinophil; Mepolizumab","score_opus":0.00611052222245248,"score_gpt":0.25817004151280665,"score_spread":0.2520595192903542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312603183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433166,0.0016143185,0.000005467326,0.00088051957,0.0001090353,0.0018194697,0.0004899607,0.000019563047,0.0007300177],"genre_scores_gemma":[0.9972142,0.00015114421,0.00002744704,0.00048790267,0.000050499697,0.00071434863,0.0000689992,0.000027080478,0.0012583605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984893,0.00013167528,0.00038842537,0.00037704027,0.0002131308,0.00040040349],"domain_scores_gemma":[0.9992079,0.00008309775,0.00018998112,0.00019832309,0.000054452685,0.0002662138],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000077727425,0.0003100509,0.0006838049,0.0002336772,0.00014004567,0.0000030917904,0.00006225922,0.000067469824,0.0013312622],"category_scores_gemma":[0.0000031096872,0.00022070343,0.00013595988,0.0001851753,0.00016842938,0.000043832126,0.000042769498,0.00010849991,0.0000010639313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06301709,0.03181069,0.43136904,0.000670588,0.009181,0.012155046,0.008006022,0.009045974,0.03151178,0.0007112842,0.004319555,0.39820194],"study_design_scores_gemma":[0.2873719,0.23035653,0.29256496,0.00015989572,0.004710424,0.000650894,0.015182329,0.0027071312,0.057263978,0.00010628685,0.10746734,0.0014583213],"about_ca_topic_score_codex":0.006308602,"about_ca_topic_score_gemma":0.0034108944,"teacher_disagreement_score":0.39674363,"about_ca_system_score_codex":0.0009257005,"about_ca_system_score_gemma":0.00081250514,"threshold_uncertainty_score":0.99958163},"labels":[],"label_agreement":null},{"id":"W4312732011","doi":"10.1183/13993003.congress-2022.3409","title":"Association of Short-Acting-β-2 Agonist (SABA) Overuse and Risk of COPD among Adult Asthma Patients","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Asthma; COPD; Association (psychology); Agonist; Medicine; B2 receptor; Internal medicine; Psychology; Receptor","score_opus":0.011916154607704009,"score_gpt":0.2935067825989839,"score_spread":0.2815906279912799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312732011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963436,0.0007840959,0.0000018772394,0.0002671487,0.00023975303,0.00091679365,0.0006430843,0.000020856745,0.00078275043],"genre_scores_gemma":[0.99692446,0.001579708,0.000037943257,0.000050545226,0.000057566183,0.00017810482,0.00016197619,0.00002186444,0.0009878238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832803,0.00031158337,0.0003229788,0.0003601113,0.00037460553,0.00030267946],"domain_scores_gemma":[0.9989861,0.00024765622,0.00027135652,0.00014571488,0.00016040662,0.0001887397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019571396,0.00019558045,0.0004305417,0.00012697796,0.00026951623,0.0000054291527,0.000056874032,0.0000773776,0.0007876307],"category_scores_gemma":[0.00005530498,0.0001794027,0.00010804009,0.00015363331,0.00021642797,0.00007611664,0.00014396774,0.00024755363,0.000002189894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015040885,0.0021537978,0.9660295,0.00012823455,0.001474041,0.00006748085,0.00047243992,0.00003197784,0.0008896909,0.000016845373,0.0014154875,0.025816374],"study_design_scores_gemma":[0.009157928,0.0023893467,0.9756139,0.000017616178,0.0011424081,0.00000831708,0.00037423798,0.0007997299,0.007558606,0.000021940761,0.0027835728,0.00013237575],"about_ca_topic_score_codex":0.00053412403,"about_ca_topic_score_gemma":0.00008682776,"teacher_disagreement_score":0.025683997,"about_ca_system_score_codex":0.00085047144,"about_ca_system_score_gemma":0.00014869847,"threshold_uncertainty_score":0.86240035},"labels":[],"label_agreement":null},{"id":"W4312742691","doi":"10.1183/13993003.congress-2022.2074","title":"Dose delivery characteristics and lung deposition of indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) and IND/MF via Breezhaler® device: An Alberta Idealised Throat (AIT) evaluation","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Indacaterol; Dry-powder inhaler; Deposition (geology); Mometasone furoate; Inhalation; Materials science; Inhaler; Lung; Drug delivery; Medicine; Biomedical engineering; Lung function; Asthma; Anesthesia; Nanotechnology; Surgery; Internal medicine","score_opus":0.024376540366950267,"score_gpt":0.3141859573800662,"score_spread":0.28980941701311597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312742691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947315,0.0025456352,0.000036082343,0.00066243554,0.00038818928,0.0013423687,0.00009273098,0.000033068933,0.00016801697],"genre_scores_gemma":[0.9962297,0.0012791541,0.0000925596,0.0011776809,0.00013932609,0.00027749114,0.0005923671,0.00003292414,0.00017879182],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978166,0.00054563937,0.0004923828,0.00051901507,0.00032147727,0.00030484443],"domain_scores_gemma":[0.9989765,0.0001377627,0.0003012929,0.0001875645,0.00015129086,0.000245544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004426636,0.00032885125,0.0005349843,0.00027233697,0.00049282593,0.000022989223,0.000059967082,0.00015754372,0.0007371303],"category_scores_gemma":[0.000009532859,0.00028896108,0.00006826099,0.00017747152,0.00021124717,0.00021814993,0.00010128437,0.0002537535,0.0000052893324],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0131314695,0.006082797,0.16477269,0.0008630045,0.004307744,0.0007819986,0.012361854,0.00044281103,0.5476922,0.00013615187,0.0013985833,0.24802873],"study_design_scores_gemma":[0.0807931,0.019896267,0.53275543,0.00021889809,0.01821501,0.0024165234,0.0016613828,0.10194785,0.23467512,0.00012212494,0.005493687,0.0018046161],"about_ca_topic_score_codex":0.00028110362,"about_ca_topic_score_gemma":0.00009146107,"teacher_disagreement_score":0.36798272,"about_ca_system_score_codex":0.0003156284,"about_ca_system_score_gemma":0.00018347977,"threshold_uncertainty_score":0.99995625},"labels":[],"label_agreement":null},{"id":"W4312847172","doi":"10.1183/13993003.congress-2022.3994","title":"Benralizumab attenuates blood and airway eosinophilia in severe asthmatics with inadequate response to anti-IL-5 neutralizing antibodies","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Benralizumab; Medicine; Eosinophilia; Sputum; Mepolizumab; Immunology; Asthma; Placebo; Exhaled nitric oxide; Prednisone; Internal medicine; Gastroenterology; Eosinophil; Spirometry; Tuberculosis; Pathology","score_opus":0.014956865815718874,"score_gpt":0.2855800193315072,"score_spread":0.2706231535157883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312847172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99131244,0.0023066008,0.0000026061014,0.0049134414,0.00014019835,0.0010013453,0.00013944581,0.00006684443,0.00011706579],"genre_scores_gemma":[0.9968121,0.00053347746,0.00020346273,0.0012770202,0.00006675918,0.00026355824,0.000035711724,0.000038515736,0.0007694111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998109,0.00037001673,0.00031819206,0.0005216423,0.00020097132,0.00048016763],"domain_scores_gemma":[0.9991564,0.0001943191,0.00009768743,0.00018337827,0.000037121175,0.00033107813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020736048,0.0003651586,0.00057336566,0.00031050388,0.00045998654,0.000021529086,0.00007435024,0.00007555188,0.00023579634],"category_scores_gemma":[0.000012790127,0.00027681177,0.000063816195,0.00028300553,0.00020285306,0.00009239904,0.00014081712,0.00023519274,0.0000087754115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0434213,0.008941807,0.7383948,0.00060775084,0.0025257606,0.018674621,0.012055432,0.003542418,0.093401186,0.00019588524,0.0039188964,0.07432013],"study_design_scores_gemma":[0.05411443,0.05262867,0.76037616,0.00035907835,0.0038548422,0.0035033168,0.0057239295,0.00058562274,0.06631307,0.000080991056,0.050899643,0.0015602275],"about_ca_topic_score_codex":0.00007202107,"about_ca_topic_score_gemma":0.000049973394,"teacher_disagreement_score":0.072759904,"about_ca_system_score_codex":0.00015313958,"about_ca_system_score_gemma":0.00019535949,"threshold_uncertainty_score":0.9999684},"labels":[],"label_agreement":null},{"id":"W4312902543","doi":"10.1183/13993003.congress-2022.807","title":"Efficacy in SOOTHE, A Phase 2b Trial of BLU-5937 In Refractory Chronic Cough, Was Not Dependant of Taste Disturbance Adverse Events","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Respiratory and Cough-Related Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bellus Health (Canada)","funders":"","keywords":"Discontinuation; Placebo; Medicine; Adverse effect; Refractory (planetary science); Chronic cough; Internal medicine; Population; Confounding; Incidence (geometry); Biology; Pathology","score_opus":0.032541369635219745,"score_gpt":0.36674652947092595,"score_spread":0.3342051598357062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312902543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99452126,0.002483808,0.0000021937105,0.0003153981,0.00037658052,0.0018667879,0.00008978361,0.000013425496,0.00033073983],"genre_scores_gemma":[0.99713373,0.0013367082,0.000009662298,0.0000948949,0.00008701456,0.0004768413,0.000038847702,0.000020966792,0.0008013314],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99773484,0.0005200721,0.00059907825,0.00041549097,0.00033622677,0.00039426697],"domain_scores_gemma":[0.9991144,0.00026657604,0.0002180695,0.00023364658,0.000032127937,0.00013519691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048945344,0.00023225496,0.00065605773,0.00028811142,0.00010514126,0.0000011718231,0.000126667,0.00011105583,0.00086407206],"category_scores_gemma":[0.00002448914,0.0001907708,0.00013925611,0.00033415906,0.00019434391,0.000064527885,0.00009593554,0.0005104795,0.000007276416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62638587,0.06716716,0.011976284,0.0004947258,0.0021571813,0.0053793346,0.0036308467,0.0029759046,0.17981082,0.00010616137,0.0008484513,0.09906727],"study_design_scores_gemma":[0.76585615,0.052497372,0.014779528,0.00020288108,0.0008296829,0.000079579724,0.00047513426,0.001215478,0.13499996,0.000027862423,0.028640987,0.00039540022],"about_ca_topic_score_codex":0.00012842595,"about_ca_topic_score_gemma":0.00006993742,"teacher_disagreement_score":0.13947028,"about_ca_system_score_codex":0.0006193955,"about_ca_system_score_gemma":0.00055636175,"threshold_uncertainty_score":0.9460983},"labels":[],"label_agreement":null},{"id":"W4313048206","doi":"10.1183/13993003.congress-2022.950","title":"The Effect of Inhaled Salbutamol on Mannitol Evoked Cough Responses: A Double-Blind Randomized Placebo Controlled 2-way Cross-Over Study","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Respiratory and Cough-Related Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Salbutamol; Placebo; Bronchoconstriction; Medicine; Mannitol; Anesthesia; Bronchodilator; Asthma; Pharmacology; Airway; Internal medicine; Chemistry; Biochemistry","score_opus":0.029006524293964442,"score_gpt":0.3908387109654875,"score_spread":0.36183218667152306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313048206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773323,0.0025805915,0.0000015723692,0.0006897736,0.00061927404,0.016481936,0.000031243453,0.0000592806,0.002204031],"genre_scores_gemma":[0.9748118,0.00037100952,0.0000015639956,0.00019910131,0.0001253592,0.01126186,0.000017603617,0.000039158138,0.013172552],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923432,0.0051105204,0.00076705555,0.0005860168,0.00065650186,0.00053673313],"domain_scores_gemma":[0.9916021,0.0073548253,0.00030108658,0.00042113432,0.000097910524,0.00022293278],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003910496,0.00045194163,0.0016645504,0.00026526963,0.0012166076,0.000042052747,0.0002086863,0.00015046417,0.0014511923],"category_scores_gemma":[0.0001597191,0.0002444171,0.00044011092,0.00031252456,0.00062185625,0.00005849325,0.00014453656,0.00072672695,0.000032168384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97858816,0.0027517884,0.003450486,0.000036282985,0.006578237,0.0022172902,0.00085018313,0.00030882246,0.0019306175,0.000047986185,0.0011143564,0.0021257692],"study_design_scores_gemma":[0.94210416,0.03336371,0.00081255496,0.000019471838,0.0028952437,0.00013570674,0.00029808446,0.00050146406,0.015822778,0.00001422725,0.0038457292,0.00018685867],"about_ca_topic_score_codex":0.00007121088,"about_ca_topic_score_gemma":0.000010825997,"teacher_disagreement_score":0.036484007,"about_ca_system_score_codex":0.00030338432,"about_ca_system_score_gemma":0.0002727456,"threshold_uncertainty_score":0.9994616},"labels":[],"label_agreement":null},{"id":"W4313170917","doi":"10.1183/13993003.congress-2022.3660","title":"Phosphoinositide-3 kinase antagonism does not reverse steroid insensitivity in severe asthma","year":2022,"lang":"en","type":"article","venue":"05.01 - Airway pharmacology and treatment","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Dexamethasone; Apoptosis; LY294002; Eosinophil; Viability assay; Endocrinology; Annexin; Internal medicine; Antagonist; Pharmacology; PI3K/AKT/mTOR pathway; Chemistry; Medicine; Asthma; Receptor; Biochemistry","score_opus":0.013615669580336913,"score_gpt":0.2808234204423921,"score_spread":0.2672077508620552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313170917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938857,0.001050263,0.000002249964,0.002742079,0.00067568704,0.0007736252,0.00032010884,0.000069993795,0.0004802964],"genre_scores_gemma":[0.9921417,0.0004289192,0.00004180541,0.0048593637,0.00016746837,0.00025603687,0.00008936806,0.00002612433,0.0019892103],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829996,0.00032896528,0.0002709074,0.0005102062,0.00019076468,0.00039917935],"domain_scores_gemma":[0.9993024,0.000117692514,0.00009141749,0.0001883302,0.000025688589,0.0002744839],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015419172,0.00029665953,0.00046154635,0.0001570322,0.00037929075,0.000009653483,0.000056301866,0.00008483802,0.0013412639],"category_scores_gemma":[0.000007001108,0.0002195007,0.00013144579,0.00014939455,0.00016888003,0.00008396884,0.00013235098,0.00029614623,0.000027923708],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025638616,0.018849384,0.27629134,0.00037502503,0.0016872984,0.086549096,0.004490007,0.00061132794,0.26525676,0.00019293526,0.020807793,0.2992504],"study_design_scores_gemma":[0.046078075,0.012167856,0.20902814,0.00007298025,0.0012431943,0.0022801498,0.002486664,0.0004896742,0.46516877,0.00008095125,0.25983357,0.0010699657],"about_ca_topic_score_codex":0.00021598798,"about_ca_topic_score_gemma":0.00006939281,"teacher_disagreement_score":0.29818043,"about_ca_system_score_codex":0.0003890734,"about_ca_system_score_gemma":0.00021875267,"threshold_uncertainty_score":0.9995716},"labels":[],"label_agreement":null}]}